Authors
Latest:
Merging Community Practices With an Academic Cancer CenterConsolidation of community oncology practices with hospital-based cancer centers is an accelerating trend that will affect future healthcare delivery models. This year, the Community Oncology Alliance reported hospital acquisitions and corporate mergers among 55% of 1338 community oncology practices surveyed, representing a 20% increase over the previous year's results.
Latest:
Journal Club Bridges Research and Practice, Improving Patient CareThree oncology nurses at the Smilow Cancer Hospital at Yale-New Haven write about the Smilow Society, an interactive and innovative journal club enabling nurses to stay abreast of important research developments, which can then be translated directly into clinical practice.
Latest:
Dr. Morrow on Patient Selection for Nipple Sparing MastectomyMonica Morrow, MD, discusses the factors that impact the decision to use nipple sparing mastectomy versus conventional mastectomy in patients with breast cancer. The decision to use a nipple sparing approach in patients is dependent on 2 considerations. These relate to the cancer as well as cosmetic appearance of the breast.
Latest:
Dr. Joshi on Rationale for Durvalumab/RT Combo in Localized Urothelial CarcinomaMonika Joshi, MD, discusses the rationale for using durvalumab in combination with radiation therapy in patients with localized urothelial carcinoma.
Latest:
Initiative Aims to Boost Clinical Trial Participation Among Asian-AmericansThe UC Davis Comprehensive Cancer Center and the National Cancer Institute (NCI)-funded National Center for Reducing Asian American Cancer Health Disparities are working to address these disparities through programs to boost participation in clinical trials, collect biospecimens, and conduct blood genomics research.
Latest:
Moon Chen on Disparities in Cancer CareMoon S. Chen Jr., PhD, MPH, associate director, Population Research and Cancer Disparities, professor, UC Davis Comprehensive Cancer Center, discusses various disparities in cancer care in underserved populations.
Latest:
Future Directions in the Management of Immune ThrombocytopeniaExpert panelists reflect on the advent of newer therapies in immune thrombocytopenia and look toward future evolutions in care.
Latest:
NY-ESO-1 Gains Momentum as a Therapeutic TargetAs the immunotherapy research field grows, NY-ESO-1 is emerging as a high-priority target for cancer vaccine development and adoptive T-cell therapies.
Latest:
Triplet Targeted Therapy May Signal a New Standard in Metastatic CRCNow, investigators are combining BRAF inhibitors with other targeted therapies in an effort to establish a new chemotherapy-free standard in patients with metastatic colorectal cancer.
Latest:
Denosumab: A Review of Its Pharmacology and Clinical ImplicationsIt is estimated that approximately 80% of all patients with diagnoses of breast cancer, prostate cancer, or multiple myeloma will develop bone metastases at some time during the course of their disease.
Latest:
Dr. Freeman on Challenges in Treatment Selection in MelanomaMorganna Freeman, DO, associate director, Melanoma and Cutaneous Oncology Program, The Angeles Clinic and Research Institute, discusses the challenges associated with treatment selection in melanoma.
Latest:
Where There’s Smoke: Are Oncology Fellows in Danger of Burnout?This moment occurred during the middle of my first year of fellowship, and I felt overwhelmed by clinical responsibilities and a seemingly insurmountable learning curve. The question dawned on me: was I suffering from burnout?
Latest:
Becoming a Champion of Change: Educating Fellows on the Costs of Cancer CareOn a recent day in hematology clinic, I stood dutifully by my attending as he sorted through bone marrow slides
Latest:
Dr. Gertz on the Outlook for Waldenstrom MacroglobulinemiaMorie A. Gertz, MD, MACP, discusses the current outlook for patients with Waldenström macroglobulinemia.
Latest:
Birtamimab Plus Standard-Of-Care in Light Chain Amyloidosis: The Phase 3 Randomized, Placebo-Controlled VITAL TrialSPONSORED CONTENT: Morie Gertz, MD, reviews data on the use of birtamimab plus standard-of-care anti-plasma cell chemotherapy in patients with light-chain amyloidosis, which was investigated in the phase 3 randomized, placebo-controlled VITAL trial.
Latest:
Dr. Sherman on the Role of Regorafenib in Liver CancerMorris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the emergence of regorafenib (Stivarga) and how it fits into the treatment of hepatocellular carcinoma (HCC).
Latest:
Dr. Sherman on Screening Obstacles in Liver CancerMorris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the issues oncologists face with screening patients for hepatocellular carcinoma (HCC) in an interview during the 10th International Liver Cancer Association (ILCA) Annual Conference.
Latest:
Optimizing Treatment in Advanced RCCMartin H. Voss, MD, provides valuable insights into determining the optimal duration of treatment with lenvatinib plus pembrolizumab in patients with advanced renal clear cell carcinoma, emphasizing the importance of close patient monitoring and the critical decision-making process involved in continuing or discontinuing treatment based on individual patient response, tolerability, and overall clinical status in real-world clinical practice settings.
Latest:
Future Management of Chronic Myeloid LeukemiaClosing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.
Latest:
Dr. Rimawi on the Promise of the HER2CLIMB-02 Trial in HER2+ Breast CancerMothaffar Fahed Rimawi, MD, discusses the promise of the phase 3 HER2CLIMB-02 trial in HER2-positive metastatic breast cancer.
Latest:
Everolimus Improves Progression-Free Survival in Patients with Previously Treated Metastatic RCCA subgroup analysis of a randomized trial showed that patients with previously treated metastatic renal cell carcinoma had significant improvement in progression-free survival when they received everolimus.
Latest:
The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment RecommendationsResearchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.
Latest:
Dr. Patnaik on Activity of SL-401 in Chronic Myelomonocytic LeukemiaMrinal Patnaik, MBBS, hematologist, Mayo Clinic, discusses the encouraging results seen in a phase II trial evaluating the activity of SL-401 in patients with advanced, high risk myeloproliferative neoplasms, including chronic myelomonocytic leukemia.
Latest:
Dr. Patnaik on a Study Examining SL-401 in Patients With Myeloproliferative NeoplasmsMrinal S. Patnaik, MBBS, hematologist, Mayo Clinic, discusses a study investigating SL-401 in patients with myeloproliferative neoplasms during the American Society of Hematology (ASH) Annual Meeting.
Latest:
Combination Therapies Explored in Pancreatic Cancer SubgroupsTo address the unmet need for better diagnostic and therapeutic modalities in pancreatic cancer, investigators at the Indiana University School of Medicine have established the Pancreatic Cancer Signature Center at the Indiana University Melvin and Bren Simon Cancer Center.
Latest:
Liver-Directed Therapy for Hepatic MalignanciesManagement of hepatic malignancies requires a multidisciplinary approach, and is based on the tumor burden, liver function, and PS of the patient.
Latest:
Developing Optimal Patient Medication InformationWashington, we have a problem. Patients continue to receive prescription medication information, which they often misunderstand or ignore.
